Btg Plc (OTCMKTS:BTGGF) – Research analysts at Jefferies Group issued their FY2019 EPS estimates for shares of BTG in a note issued to investors on Wednesday, May 16th. Jefferies Group analyst P. Welford anticipates that the company will earn $0.48 per share for the year. Jefferies Group also issued estimates for BTG’s FY2020 earnings at $0.50 EPS, FY2021 earnings at $0.61 EPS and FY2022 earnings at $0.75 EPS.
Separately, Zacks Investment Research lowered BTG from a “buy” rating to a “hold” rating in a research report on Thursday, March 29th.
BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, Asia, and internationally. It operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing. The Interventional Medicine segment offers interventional oncology products and systems, such as beads and TheraSphere for treatment of liver cancer; and GALIL medical system, a cryoablation technology for use in kidney cancer and other indications.
Receive News & Ratings for BTG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG and related companies with MarketBeat.com's FREE daily email newsletter.